C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering
Provided By GlobeNewswire
Last update: Oct 16, 2025
$125 Million in Upfront Proceeds Expected to Fund Next Phase of Cemsidomide Multiple Myeloma Development Including Registrational Phase 2 Trial in Combination with Dexamethasone and Phase 1b Trial in Combination with Elranatamab
Read more at globenewswire.com
